<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1860</journal-id><journal-id journal-id-type="pmc-domain">fcimb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10347389</article-id><article-id pub-id-type="pmcid-ver">PMC10347389.1</article-id><article-id pub-id-type="pmcaid">10347389</article-id><article-id pub-id-type="pmcaiid">10347389</article-id><article-id pub-id-type="pmid">37457950</article-id><article-id pub-id-type="doi">10.3389/fcimb.2023.1167638</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cellular and Infection Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Microbiology and prognostic prediction model of bloodstream infection in patients with hematological malignancies</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jinjin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1984303"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="M">Mengyao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/663921"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="A">Ailin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1177389"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="H">Hui</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1981146"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mu</surname><given-names initials="M">Mingchun</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2082115"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="X">Xueting</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Niu</surname><given-names initials="T">Ting</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1619960"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Hematology, West China Hospital, Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Gastric Cancer Center, West China Hospital, Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Medical Discipline Construction, West China Hospital, Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Juan Carlos Rodriguez Diaz, Hospital General Universitario de Alicante, Spain</p></fn><fn fn-type="edited-by"><p>Reviewed by: &#304;lhami &#199;elik, Department of Infectious Diseases, T&#252;rkiye; Gemma Jim&#233;nez-Guerra, Westeros Hospital, Spain</p></fn><corresp id="fn001">*Correspondence: Ting Niu, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:tingniu@sina.com">tingniu@sina.com</email></corresp><fn fn-type="equal" id="fn003"><p>&#8224;These authors have contributed equally to this work and share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">427506</issue-id><elocation-id>1167638</elocation-id><history><date date-type="received"><day>18</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>15</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-07-17 11:25:09.120"><day>17</day><month>07</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Wang, Wang, Zhao, Zhou, Mu, Liu and Niu</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Wang, Wang, Zhao, Zhou, Mu, Liu and Niu</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcimb-13-1167638.pdf"/><abstract><sec><title>Background</title><p>In recent years, with the continuous development of treatments for hematological malignancies (HMs), the remission and survival rates of patients with HMs have been significantly improved. However, because of severe immunosuppression and long-term recurrent neutropenia during treatment, the incidence and mortality of bloodstream infection (BSI) were all high in patients with HMs. Therefore, we analyzed pathogens&#8217; distribution and drug-resistance patterns and developed a nomogram for predicting 30-day mortality in patients with BSIs among HMs.</p></sec><sec><title>Methods</title><p>In this retrospective study, 362 patients with positive blood cultures in HMs were included from June 2015 to June 2020 at West China Hospital of Sichuan University. They were randomly divided into the training cohort (n = 253) and the validation cohort (n = 109) by 7:3. A nomogram for predicting 30-day mortality after BSIs in patients with HMs was established based on the results of univariate and multivariate logistic regression. C-index, calibration plots, and decision curve analysis were used to evaluate the nomogram.</p></sec><sec><title>Results</title><p>Among 362 patients with BSIs in HMs, the most common HM was acute myeloid leukemia (48.1%), and the most common pathogen of BSI was gram-negative bacteria (70.4%). The final nomogram included the septic shock, relapsed/refractory HM, albumin &lt;30g/l, platelets &lt;30&#215;10<sup>9</sup>/l before BSI, and inappropriate empiric antibiotic treatment. In the training and validation cohorts, the C-indexes (0.870 and 0.825) and the calibration plots indicated that the nomogram had a good performance. The decision curves in both cohorts showed that the nomogram model for predicting 30-day mortality after BSI was more beneficial than all patients with BSIs or none with BSIs.</p></sec><sec><title>Conclusion</title><p>In our study, gram-negative bacterial BSIs were predominant in patients with HMs. We developed and validated a nomogram with good predictive ability to help clinicians evaluate the prognosis of patients.</p></sec></abstract><kwd-group><kwd>bloodstream infection</kwd><kwd>hematological malignancy</kwd><kwd>nomogram</kwd><kwd>model</kwd><kwd>microbiology</kwd><kwd>30-day mortality</kwd><kwd>risk factor</kwd></kwd-group><funding-group><funding-statement>This work was supported by Incubation Program for Clinical Trials (No. 19HXFH030), Achievement Transformation Project (No. CGZH21001), 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (No. ZYJC21007), Translational Research Grant of NCRCH (No. 2021WWB03), Chengdu Science and Technology Program (No. 2022-YF05-01444-SN), Key Research&#160;and Development Program of Sichuan Province (No. 2023YFS0031), and National Key Research and Development Program of China (No. 2022YFC2502600, 2022YFC2502603).</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="2"/><equation-count count="0"/><ref-count count="54"/><page-count count="12"/><word-count count="4929"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Clinical Microbiology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Hematological malignancies (HMs) are diseases originating from or implicating the hematologic system and hematopoietic tissue. The treatment of HMs includes chemotherapy, immunotherapy, targeted therapy, and hematopoietic stem cell transplantation (<xref rid="B5" ref-type="bibr">Auberger et&#160;al., 2020</xref>). In recent years, with the continuous development of treatments for HMs, the remission and survival rates of patients with HMs have significantly improved. However, because of severe immunosuppression and long-term recurrent neutropenia during treatment, the incidence (20.8%-24.1%) and mortality (10%-32%) of bloodstream infection (BSI) were all high in patients with HMs (<xref rid="B30" ref-type="bibr">N&#248;rgaard et&#160;al., 2006</xref>; <xref rid="B4" ref-type="bibr">&#197;ttman et&#160;al., 2015</xref>; <xref rid="B44" ref-type="bibr">Trecarichi et&#160;al., 2015</xref>; <xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B9" ref-type="bibr">Chen et&#160;al., 2021</xref>; <xref rid="B31" ref-type="bibr">Okamoto et&#160;al., 2021</xref>; <xref rid="B53" ref-type="bibr">Zhao et&#160;al., 2022</xref>). Meanwhile, compared with solid tumors, patients with HMs had a higher risk for BSIs (<xref rid="B27" ref-type="bibr">Marin et&#160;al., 2014</xref>). A 14-year longitudinal surveillance study showed that the incidence of BSIs in patients with HMs was three times higher than that of other cancer (<xref rid="B37" ref-type="bibr">Schelenz et&#160;al., 2013</xref>).</p><p>BSI has many unfavorable effects on patients with HMs, such as the increase in mortality, the addition of medical bills, and the prolongation of the hospitalization period (<xref rid="B24" ref-type="bibr">Liao et&#160;al., 2021</xref>). Therefore, timely and effective control of BSI is vital for patients with HMs. On the one hand, antibiotic therapy is crucial to patients with BSIs, and no other treatment can replace the efficacy of antibiotics. Doctors usually treat patients with an empiric antibiotic to control BSIs and then adjust the antibiotic based on the drug sensitivity test results, as it takes some time to isolate the pathogens by blood culture. Investigating pathogens&#8217; distribution and drug-resistance patterns contribute to choosing the appropriate empiric antibiotics (<xref rid="B19" ref-type="bibr">Kadri et&#160;al., 2021</xref>).</p><p>On the other hand, it was essential to identify the risk factors for mortality in patients with BSIs, and then conduct early intervention and management (<xref rid="B43" ref-type="bibr">Timsit et&#160;al., 2020</xref>). Studies have explored the risk factors of prognosis for patients with BSIs in hematological diseases (<xref rid="B46" ref-type="bibr">Tumbarello et&#160;al., 2012</xref>; <xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B1" ref-type="bibr">Albasanz-Puig et&#160;al., 2021</xref>; <xref rid="B38" ref-type="bibr">Shi et&#160;al., 2022</xref>; <xref rid="B53" ref-type="bibr">Zhao et&#160;al., 2022</xref>). These risk factors included age &gt;60, relapsed or uncontrol malignancies, nosocomial infection, prolonged neutropenia, profound neutropenia, inappropriate empiric antibiotics, albumin &lt;30g/l, BSI with multiple drug-resistant (MDR) bacteria, placement of the central venous catheter (CVC), placement of the urinary catheter, decreased white blood cell, and so on. Many prediction models were applied to assess outcomes for patients at high risk of various diseases (<xref rid="B49" ref-type="bibr">Woo et&#160;al., 2016</xref>; <xref rid="B51" ref-type="bibr">Yang et&#160;al., 2020</xref>; <xref rid="B3" ref-type="bibr">Asami et&#160;al., 2022</xref>; <xref rid="B54" ref-type="bibr">Zhu et&#160;al., 2022</xref>). Nevertheless, there were few models for the prognosis of patients with BSIs in HMs (<xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B53" ref-type="bibr">Zhao et&#160;al., 2022</xref>). Meanwhile, these models may not apply to patients with BSIs in this region due to regional differences.</p><p>West China Hospital of Sichuan University is one of the largest diagnosis and treatment centers for difficult miscellaneous diseases in Western China, and its data are representative. Therefore, based on data from our hospital, we analyzed pathogens&#8217; distribution and drug-resistance patterns and established a nomogram model for predicting 30-day mortality in patients with BSIs among HMs, to provide evidence for the prevention and treatment of patients with BSIs in HMs.</p></sec><sec id="s2"><title>Methods</title><sec id="s2_1"><title>Setting and study design</title><p>This retrospective study was conducted at the hematology department (215 beds) of West China Hospital, a national center for diagnosing and treating complex and critical diseases in Western China. The subjects in this study covered patients with positive blood cultures (bacteria or fungi) in HMs from June 2015 to June 2020. West China Hospital of Sichuan University Ethics Committee approved this study and waived informed consent because this study was retrospectively designed. We followed the following inclusion criteria to screen patients: (1) positive blood culture; (2) patient diagnosed with HM; (3) complete clinical data. The exclusion criteria were as follows: (1) patient diagnosed with non-HM; (2) incomplete clinical data; (3) patient with multiple positive blood cultures with the same pathogen during the same hospital stay; they were counted once.</p></sec><sec id="s2_2"><title>Data collection</title><p>Data were extracted from the Hospital Information System (HIS) of West China Hospital of Sichuan University. The details were as follows: ID number, gender, age, temperature, pathogens of BSIs, results of drug sensitivity test, blood pressure, state of disease, hematopoietic stem cell transplantation, nosocomial infection, length of stay before BSI, concurrent infection, white blood cell count, neutrophil count, platelet count, albumin level, procalcitonin (PCT), C-reactive protein (CRP), prothrombin time, activated partial thromboplastin time, D-dimer, invasive operation (urinary catheter, CVC), or peripherally inserted central catheter (PICC)), empiric antibiotic therapy, chemotherapy regimen, and outcomes at 30-day after BSI.</p></sec><sec id="s2_3"><title>Definitions</title><p>Patients with positive blood culture (excluding pollution) who had a fever (&gt;38&#176;C) and at the same time one or more symptoms, including chill, low oxygen saturation, hypotension, cold moist limbs, and disturbance of consciousness, were identified as true BSI (<xref rid="B2" ref-type="bibr">Amanati et&#160;al., 2021</xref>). Septic shock was defined as the vasopressor requirement for maintaining mean arterial pressure &#8805;65mmHg or serum lactate level &#8805;2mmol/l (<xref rid="B39" ref-type="bibr">Singer et&#160;al., 2016</xref>). Disseminated intravascular coagulation (DIC) was diagnosed with the Chinese DIC scoring system (<xref rid="B25" ref-type="bibr">Luo et&#160;al., 2019</xref>). MDR bacteria were defined as resistant to three or more antibacterial agents (<xref rid="B26" ref-type="bibr">Magiorakos et&#160;al., 2012</xref>). Empiric antibiotic therapy was defined as one or more antibiotics the patient received within 48 hours of being diagnosed with BSI (time to draw a positive blood culture specimen). Empiric antibiotic therapy was deemed appropriate if at least one of the empiric antibiotics was sensitive <italic toggle="yes">in vitro</italic> drug sensitivity test; otherwise, it was considered inappropriate empiric antibiotic therapy. Absolute neutrophil counts &lt;0.5&#215;10<sup>9</sup>/l and &lt;0.1&#215;10<sup>9</sup>/l were defined as neutropenia and profound neutropenia.</p></sec><sec id="s2_4"><title>Statistical analysis</title><p>A database was established with Excel, and statistical analysis was performed with IBM SPSS 26.0. All cases were randomly divided into a training cohort (n =253) and a validation cohort (n =109) by 7:3. Continuous variables were expressed with mean &#177; standard deviation or median (IQR) according to the distribution pattern, and t-test or Mann-Whitney U test was used to the comparison between two cohorts. Frequency and proportion were applied to represent classified variables, and the comparison between two cohorts was conducted by Chi-square test or Fisher&#8217;s exact test. The 30-day mortality risk factors were analyzed by binary logistic regression. Variables with p&lt;0.05 in the univariate logistic regression analysis were included in the multivariate logistic regression analysis. Based on the result of multivariate logistic regression analysis, we used the package of rms in R version 4.1.1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.r-project.org/" ext-link-type="uri">http://www.r-project.org/</ext-link>) to plot the nomogram. The C-index was used to evaluate the discrimination of the nomogram. If the C-index is larger, the discrimination of the nomogram model is better. The accuracy (the extent to which the nomogram predicted 30-day mortality in accordance with actual mortality) of the nomogram was assessed by calibration plots. Calibration at a 45&#176; diagonal is best, and above or below this diagonal indicates under-prediction or over-prediction. Decision curve analysis (DCA) was conducted to evaluate the net clinical benefit by quantifying net benefits at different threshold probabilities.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>Patient characteristics</title><p>A total of 362 patients who had HMs with BSIs were included in the final analysis, 174 with acute myeloid leukemia, 74 with acute lymphocytic leukemia, 58 with non-Hodgkin lymphoma, and 56 with other HMs. All patients were randomly divided into the training cohort (n = 253) and the validation cohort (n = 109) by 7:3. The detailed characteristics of all patients are shown in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>. In all patients with an average age of 42.4 years, the male accounted for 64.6%, while the female accounted for 35.4%. The state of 108 patients with HMs was relapsed/refractory. A minority (6.9%) received hematopoietic stem cell transplantation, and a majority (86.7%) had concurrent pulmonary infections. Neutropenia existed in 79.3% of patients, and secondary DIC occurred in 20%. BSIs with MDR bacteria occurred in 204 patients. 35.1% of all patients received inappropriate empiric antibiotic therapy. 30-day mortality in patients with HMs after BSIs was 29%. Most variables were balanced between the training and validation cohorts, except for the PCT (p=0.002) (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Baseline characteristics of the training and validation cohorts.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="left" rowspan="1" colspan="1">All subjects<break/>(<italic toggle="yes">n</italic> = 362)</th><th valign="top" align="left" rowspan="1" colspan="1">Training cohort<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;253)</th><th valign="top" align="left" rowspan="1" colspan="1">Validation cohort<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;109)</th><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Male</td><td valign="top" align="left" rowspan="1" colspan="1">234 (64.6)</td><td valign="top" align="left" rowspan="1" colspan="1">164 (64.8)</td><td valign="top" align="left" rowspan="1" colspan="1">70 (64.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Female</td><td valign="top" align="left" rowspan="1" colspan="1">128 (35.4)</td><td valign="top" align="left" rowspan="1" colspan="1">89 (35.2)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (35.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, mean &#177; SD, years</td><td valign="top" align="left" rowspan="1" colspan="1">42.4 &#177; 16.4</td><td valign="top" align="left" rowspan="1" colspan="1">43.4 &#177; 16.1</td><td valign="top" align="left" rowspan="1" colspan="1">40.1 &#177; 16.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.079</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pathogens, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.348</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Gram-negative bacteria</td><td valign="top" align="left" rowspan="1" colspan="1">255 (70.4)</td><td valign="top" align="left" rowspan="1" colspan="1">184 (72.7)</td><td valign="top" align="left" rowspan="1" colspan="1">71 (65.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Gram-positive bacteria</td><td valign="top" align="left" rowspan="1" colspan="1">87 (24.0)</td><td valign="top" align="left" rowspan="1" colspan="1">56 (22.1)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (28.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Fungi</td><td valign="top" align="left" rowspan="1" colspan="1">20 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (5.1)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Septic shock, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">78 (21.5)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (23.7)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.163</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Relapsed/refractory HMs, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">108 (29.8)</td><td valign="top" align="left" rowspan="1" colspan="1">78 (30.8)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (27.5)</td><td valign="top" align="left" rowspan="1" colspan="1">0.535</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hematopoietic stem cell transplantation, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (6.9)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (7.9)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (4.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.273</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nosocomial infection, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">326 (90.1)</td><td valign="top" align="left" rowspan="1" colspan="1">226 (89.3)</td><td valign="top" align="left" rowspan="1" colspan="1">100 (91.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.568</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Length of stay before BSI, median (IQR), days</td><td valign="top" align="left" rowspan="1" colspan="1">18 (10,31)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (9, 29)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (11, 38)</td><td valign="top" align="left" rowspan="1" colspan="1">0.495</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Concurrent pulmonary infection, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">314 (86.7)</td><td valign="top" align="left" rowspan="1" colspan="1">224 (88.5)</td><td valign="top" align="left" rowspan="1" colspan="1">90 (82.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.131</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Concurrent intestinal infection, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (8.7)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.688</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Concurrent perianal infection, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">43 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">32 (12.6)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (10.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.596</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">White blood cell count, median (IQR), 10<sup>9</sup>/l</td><td valign="top" align="left" rowspan="1" colspan="1">0.42 (0.14, 2.86)</td><td valign="top" align="left" rowspan="1" colspan="1">0.38 (0.13, 3.26)</td><td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.18, 2.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.319</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neutropenia, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">287 (79.3)</td><td valign="top" align="left" rowspan="1" colspan="1">201 (79.4)</td><td valign="top" align="left" rowspan="1" colspan="1">86 (78.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Profound neutropenia, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">236 (65.2)</td><td valign="top" align="left" rowspan="1" colspan="1">168 (66.4)</td><td valign="top" align="left" rowspan="1" colspan="1">68 (62.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.462</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Albumin &lt;30g/l, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">115 (31.8)</td><td valign="top" align="left" rowspan="1" colspan="1">86 (34.0)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (26.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.178</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PCT, median (IQR), ng/ml</td><td valign="top" align="left" rowspan="1" colspan="1">0.79 (0.25, 6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1.28 (0.29, 6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.49 (0.19, 2.52)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CRP, median (IQR), mg/l</td><td valign="top" align="left" rowspan="1" colspan="1">82.47 (44.3, 123.11)</td><td valign="top" align="left" rowspan="1" colspan="1">84.2 (50.08, 124.42)</td><td valign="top" align="left" rowspan="1" colspan="1">76.4 (36.85, 121.03)</td><td valign="top" align="left" rowspan="1" colspan="1">0.224</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Platelets &lt;30&#215;10<sup>9</sup>/l before BSI, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">240 (66.3)</td><td valign="top" align="left" rowspan="1" colspan="1">172 (68.0)</td><td valign="top" align="left" rowspan="1" colspan="1">68 (62.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.333</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Platelets &lt;30&#215;10<sup>9</sup>/l after BSI, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">266 (73.5)</td><td valign="top" align="left" rowspan="1" colspan="1">192 (75.9)</td><td valign="top" align="left" rowspan="1" colspan="1">74 (67.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.121</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placement of urinary catheter, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">50 (13.8)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (15.4)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (10.1)</td><td valign="top" align="left" rowspan="1" colspan="1">0.178</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placement of PICC/CVC, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">174 (48.1)</td><td valign="top" align="left" rowspan="1" colspan="1">122 (48.2)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (47.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Secondary DIC, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">73 (20.2)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (20.6)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (19.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.887</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BSI with MDR bacteria, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">204 (56.4)</td><td valign="top" align="left" rowspan="1" colspan="1">143 (56.5)</td><td valign="top" align="left" rowspan="1" colspan="1">61 (56.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Inappropriate empiric antibiotic treatment, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">127 (35.1)</td><td valign="top" align="left" rowspan="1" colspan="1">86 (34.0)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (37.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.549</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Combined empiric antibiotic treatment, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">268 (74.0)</td><td valign="top" align="left" rowspan="1" colspan="1">188 (74.3)</td><td valign="top" align="left" rowspan="1" colspan="1">80 (73.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.896</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chemotherapy regimen containing glucocorticoid, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">142 (39.2)</td><td valign="top" align="left" rowspan="1" colspan="1">101 (39.9)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (37.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.726</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">30-day mortality, <italic toggle="yes">n</italic> (%)</td><td valign="top" align="left" rowspan="1" colspan="1">105 (29)</td><td valign="top" align="left" rowspan="1" colspan="1">72 (28.5)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (30.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.801</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><title>Microbiology</title><p>Three hundred sixty-two pathogens were isolated from blood culture, including gram-negative bacteria (70.4%), gram-positive bacteria (24%), and fungi (5.5%) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). The most common gram-negative bacterium was <italic toggle="yes">Escherichia coli</italic>, accounting for 25.1%, followed by <italic toggle="yes">Klebsiella pneumoniae</italic> (16.0%) and <italic toggle="yes">Pseudomonas aeruginosa</italic> (11.1%). The common gram-positive bacteria were coagulase-negative staphylococci (7.7%), <italic toggle="yes">Enterococcus faecium</italic> (7.5%), and <italic toggle="yes">Staphylococcus aureus</italic> (4.7%). Seven strains of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) and 21 strains of methicillin-resistant coagulase-negative staphylococcus (MRCNS) were detected in all of <italic toggle="yes">Staphylococcus aureus</italic> and coagulase-negative staphylococci. The most common fungus was <italic toggle="yes">Candida tropicalis</italic>, accounting for about 2.8%. Although the proportion of gram-negative bacteria, gram-positive bacteria, and fungi fluctuated from 2015 to 2020, gram-negative bacteria were still dominant (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Distribution <bold>(A)</bold> and trend <bold>(B)</bold> in pathogens of BSIs among patients with HMs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-13-1167638-g001.jpg"/></fig><p>The results of the drug sensitivity test for the common pathogens are exhibited in <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>. <italic toggle="yes">Escherichia coli</italic> had the lowest rate of antibiotic resistance to amikacin (4.3%), followed by meropenem (8.7%) and imipenem (9.8%). The rates of antibiotic resistance of <italic toggle="yes">Klebsiella pneumoniae</italic> to amikacin, imipenem, and meropenem were 6.8%, 20.6%, and 22.4%, respectively. <italic toggle="yes">Pseudomonas aeruginosa</italic> had the lowest rates of antibiotic resistance to amikacin and ciprofloxacin, which were 2.5%. MRSA had no antibiotic resistance to tigecycline, linezolid, and vancomycin. MRCNS was completely sensitive to tigecycline and vancomycin. <italic toggle="yes">Enterococcus faecium</italic> had no resistance to tigecycline and linezolid. Fungal resistance was low to caspofungin (5%) and micafungin (5%). Meanwhile, no fungus resistant to amphotericin B was found in this study.</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Analysis of drug-resistance in BSIs with gram-negative bacteria <bold>(A)</bold>, gram-positive bacteria <bold>(B)</bold>, and fungi <bold>(C)</bold> among patients with HMs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-13-1167638-g002.jpg"/></fig></sec><sec id="s3_3"><title>Establishment of a nomogram for predicting 30-day mortality after BSI</title><p>In the training cohort, univariate logistic regression analysis showed that septic shock, relapsed/refractory HM, length of stay before BSI, concurrent pulmonary infection, concurrent perianal infection, neutropenia, albumin &lt;30g/l, platelets &lt;30&#215;10<sup>9</sup>/l before BSI, platelets &lt;30&#215;10<sup>9</sup>/l after BSI, placement of the urinary catheter, secondary DIC, inappropriate empiric antibiotic treatment, combined empiric antibiotic treatment, and chemotherapy regimen containing glucocorticoid were associated with 30-day mortality after BSI (p&lt;0.05 for all, <xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). Further multivariate logistic regression analysis revealed that septic shock (p&lt;0.001, OR=6.548, 95%CI: 3.042-14.092), relapsed/refractory HM (p=0.008, OR=2.811, 95%CI: 1.317-6.002), albumin &lt;30g/l (P&lt;0.001, OR=7.640, 95%CI: 3.529-16.542), platelets &lt;30&#215;10<sup>9</sup>/l before BSI (P&lt;0.001, OR=9.761, 95%CI: 3.511-27.132), and inappropriate empiric antibiotic treatment (P=0.002, OR=3.213, 95%CI: 1.522-6.785) were independent risk factors for 30-day mortality after BSI in patients with HMs (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). Based on the result of multivariate logistic regression analysis, we established a visual nomogram for predicting 30-day mortality after BSI in patients with HMs (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3</bold>
</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Univariate and multivariate logistic regression analyses of 30-day mortality in the training cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="3" align="center" rowspan="1">Univariate analysis</th><th valign="top" colspan="3" align="center" rowspan="1">Multivariate analysis</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="left" rowspan="1" colspan="1">OR (95%CI)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th><th valign="top" align="left" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="center" rowspan="1" colspan="1">OR (95%CI)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">1.759 (0.962, 3.216)</td><td valign="top" align="center" rowspan="1" colspan="1">0.067</td><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age &#8805;60 years</td><td valign="top" align="left" rowspan="1" colspan="1">0.728 (0.357, 1.487)</td><td valign="top" align="center" rowspan="1" colspan="1">0.384</td><td valign="top" align="left" rowspan="1" colspan="1">Age &#8805;60 years</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pathogens</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="center" rowspan="1" colspan="1">0.999</td><td valign="top" align="left" rowspan="1" colspan="1">Pathogens</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gram-negative bacteria</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Gram-negative bacteria</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gram-positive bacteria</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Gram-positive bacteria</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fungi</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Fungi</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Septic shock</td><td valign="top" align="left" rowspan="1" colspan="1">8.078 (4.248, 15.358)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Septic shock</td><td valign="top" align="center" rowspan="1" colspan="1">6.548 (3.042, 14.092)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Relapsed/refractory HMs</td><td valign="top" align="left" rowspan="1" colspan="1">1.979 (1.116, 3.511)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Relapsed/refractory HMs</td><td valign="top" align="center" rowspan="1" colspan="1">2.811 (1.317, 6.002)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.008</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hematopoietic stem cell transplantation</td><td valign="top" align="left" rowspan="1" colspan="1">1.392 (0.532, 3.644)</td><td valign="top" align="center" rowspan="1" colspan="1">0.501</td><td valign="top" align="left" rowspan="1" colspan="1">Hematopoietic stem cell transplantation</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nosocomial infection</td><td valign="top" align="left" rowspan="1" colspan="1">1.951(0.712, 5.347)</td><td valign="top" align="center" rowspan="1" colspan="1">0.194</td><td valign="top" align="left" rowspan="1" colspan="1">Nosocomial infection</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Length of stay before BSI, days</td><td valign="top" align="left" rowspan="1" colspan="1">1.017 (1.005, 1.030)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.007</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Length of stay before BSI, days</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.055</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Concurrent pulmonary infection</td><td valign="top" align="left" rowspan="1" colspan="1">3.858 (1.130, 13.177)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.031</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Concurrent pulmonary infection</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.238</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Concurrent intestinal infection</td><td valign="top" align="left" rowspan="1" colspan="1">0.938 (0.352, 2.500)</td><td valign="top" align="center" rowspan="1" colspan="1">0.897</td><td valign="top" align="left" rowspan="1" colspan="1">Concurrent intestinal infection</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Concurrent perianal infection</td><td valign="top" align="left" rowspan="1" colspan="1">2.186 (1.022, 4.674)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.044</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Concurrent perianal infection</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.233</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">White blood cell count, 10<sup>9</sup>/l</td><td valign="top" align="left" rowspan="1" colspan="1">0.955 (0.977, 1.012)</td><td valign="top" align="center" rowspan="1" colspan="1">0.555</td><td valign="top" align="left" rowspan="1" colspan="1">White blood cell count, 10<sup>9</sup>/l</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neutropenia</td><td valign="top" align="left" rowspan="1" colspan="1">2.569 (1.143, 5.774)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.022</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Neutropenia</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.190</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Profound neutropenia</td><td valign="top" align="left" rowspan="1" colspan="1">1.213 (0.674, 2.183)</td><td valign="top" align="center" rowspan="1" colspan="1">0.519</td><td valign="top" align="left" rowspan="1" colspan="1">Profound neutropenia</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Albumin &lt;30g/l</td><td valign="top" align="left" rowspan="1" colspan="1">5.691 (3.153, 10.272)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Albumin &lt;30g/l</td><td valign="top" align="center" rowspan="1" colspan="1">7.640 (3.529, 16.542)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PCT, ng/ml</td><td valign="top" align="left" rowspan="1" colspan="1">1.010 (0.997, 1.022)</td><td valign="top" align="center" rowspan="1" colspan="1">0.137</td><td valign="top" align="left" rowspan="1" colspan="1">PCT, ng/ml</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CRP, mg/l</td><td valign="top" align="left" rowspan="1" colspan="1">1.003 (1.000, 1.007)</td><td valign="top" align="center" rowspan="1" colspan="1">0.055</td><td valign="top" align="left" rowspan="1" colspan="1">CRP, mg/l</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Platelets &lt;30&#215;10<sup>9</sup>/l before BSI</td><td valign="top" align="left" rowspan="1" colspan="1">6.422 (2.789, 14.788)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Platelets &lt;30&#215;109/l before BSI</td><td valign="top" align="center" rowspan="1" colspan="1">9.761 (3.511, 27.132)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Platelets &lt;30&#215;10<sup>9</sup>/l after BSI</td><td valign="top" align="left" rowspan="1" colspan="1">3.948 (1.701, 9.166)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Platelets &lt;30&#215;109/l after BSI</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.312</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placement of urinary catheter</td><td valign="top" align="left" rowspan="1" colspan="1">3.729 (1.845, 7.537)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Placement of urinary catheter</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.274</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Placement of PICC/CVC</td><td valign="top" align="left" rowspan="1" colspan="1">0.875 (0.506, 1.512)</td><td valign="top" align="center" rowspan="1" colspan="1">0.632</td><td valign="top" align="left" rowspan="1" colspan="1">Placement of PICC/CVC</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Secondary DIC</td><td valign="top" align="left" rowspan="1" colspan="1">6.422 (2.789, 14.788)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Secondary DIC</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.124</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BSI with MDR bacteria</td><td valign="top" align="left" rowspan="1" colspan="1">1.109 (0.638, 1.927)</td><td valign="top" align="center" rowspan="1" colspan="1">0.714</td><td valign="top" align="left" rowspan="1" colspan="1">BSI with MDR bacteria</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Inappropriate empiric antibiotic treatment</td><td valign="top" align="left" rowspan="1" colspan="1">2.044 (1.163, 3.590)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.013</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Inappropriate empiric antibiotic treatment</td><td valign="top" align="center" rowspan="1" colspan="1">3.213 (1.522, 6.785)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Combined empiric antibiotic treatment</td><td valign="top" align="left" rowspan="1" colspan="1">3.136</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Combined empiric antibiotic treatment</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.214</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chemotherapy regimen containing glucocorticoid</td><td valign="top" align="left" rowspan="1" colspan="1">2.093 (1.202, 3.645)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.009</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Chemotherapy regimen containing glucocorticoid</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.410</td></tr></tbody></table><table-wrap-foot><fn><p>The bold values means &#8220;p&lt;0.05&#8221;. A p &lt;0.05 was statistically significant. </p></fn></table-wrap-foot></table-wrap><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>Nomogram for predicting 30-day mortality after BSIs in patients with HMs. (The &#8220;Yes&#8221; or &#8220;No&#8221; of each variable corresponded to the score on the &#8220;Points&#8221; axis, then the individual scores were added together to obtain the total score, the total score on the &#8220;Total points&#8221; axis corresponded to the dot of &#8220;Death&#8221; axis, which was the predicted probability of 30-day mortality).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-13-1167638-g003.jpg"/></fig></sec><sec id="s3_4"><title>Calibration and validation of the nomogram</title><p>The C-indexes of the nomogram were 0.870 (95%CI: 0.820-0.921) and 0.825 (95%CI: 0.737-0.912) in the training and validation cohorts, which indicated that the model had good discrimination. As shown in <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4</bold>
</xref>, the calibration plots of the nomogram in both cohorts suggested that 30-day mortality after BSI predicted by the nomogram model was consistent with the actual mortality. Decision curves were used to evaluate the net clinical benefit of the nomogram model. The decision curves of the nomogram in the training and validation cohorts showed that the model for predicting 30-day mortality after BSI was more beneficial than all patients with BSIs or none with BSIs (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5</bold>
</xref>).</p><fig position="float" id="f4" orientation="portrait"><label>Figure&#160;4</label><caption><p>Calibration plots of the nomogram in the training cohort <bold>(A)</bold> and the validation cohort <bold>(B)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-13-1167638-g004.jpg"/></fig><fig position="float" id="f5" orientation="portrait"><label>Figure&#160;5</label><caption><p>Decision curve analysis for the training cohort <bold>(A)</bold> and the validation cohort <bold>(B)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-13-1167638-g005.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>BSI is a common infection in patients with HMs. BSI negatively impacts patients with HMs, which may lead to death (<xref rid="B22" ref-type="bibr">Kochanek et&#160;al., 2019</xref>). Based on the complexity and high mortality of BSIs in HMs, we retrospectively analyzed the hospital data to identify pathogens&#8217; distribution and antibiotic resistance. Meanwhile, we developed a nomogram for predicting the 30-day mortality of patients with BSIs in HMs. Our study represented a large-scale, single-center experience, and the results deepened our understanding of BSIs in patients with HMs.</p><p>Acute leukemia (acute myeloid leukemia and acute lymphocytic leukemia) was the most common HMs with BSIs in our study. The reason may be that patients with acute leukemia frequently received intensive chemotherapy and had long-term neutropenia (<xref rid="B15" ref-type="bibr">Garcia-Vidal et&#160;al., 2018</xref>). Neutropenia was often associated with life-threatening infections during cytotoxic chemotherapy (<xref rid="B23" ref-type="bibr">Kuo et&#160;al., 2017</xref>). Research showed that the rate of infections was 86.9% in patients with acute leukemia during the induction chemotherapy (<xref rid="B20" ref-type="bibr">Kato et&#160;al., 2018</xref>). Therefore, active infection control measures were necessary for patients with acute leukemia.</p><p>In the early days, researchers generally observed that gram-positive bacteria were the most common in BSIs (<xref rid="B32" ref-type="bibr">Ortega et&#160;al., 2005</xref>; <xref rid="B36" ref-type="bibr">Safdar et&#160;al., 2006</xref>; <xref rid="B18" ref-type="bibr">Huttunen et&#160;al., 2015</xref>). This may be associated with the prophylactic use of fluoroquinolone (<xref rid="B21" ref-type="bibr">Kern et&#160;al., 2018</xref>). However, this trend has reversed in recent years, and BSIs with gram-negative bacteria were more prevalent than gram-positive bacteria (<xref rid="B10" ref-type="bibr">Chen et&#160;al., 2017</xref>; <xref rid="B29" ref-type="bibr">Mimura et&#160;al., 2020</xref>; <xref rid="B17" ref-type="bibr">Haddad et&#160;al., 2021</xref>). Our study also confirmed the changing trend. We collected 362 pathogens, mainly gram-negative bacteria (70.4%), the most common being <italic toggle="yes">Escherichia coli</italic>. A retrospective study showed that BSIs with gram-negative bacteria accounted for 65% from 2007 to 2017, of which <italic toggle="yes">Escherichia coli</italic> was the most common (<xref rid="B17" ref-type="bibr">Haddad et&#160;al., 2021</xref>). A study from China suggested that gram-negative bacteria accounted for 64.7%, gram-positive bacteria accounted for 27.7%, and fungi accounted for 7.7% of BSIs in patients with HMs (<xref rid="B9" ref-type="bibr">Chen et&#160;al., 2021</xref>). In the present study, BSIs with gram-positive bacteria accounted for 24%, and coagulase-negative staphylococci were the most common, similar to other reports (<xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B2" ref-type="bibr">Amanati et&#160;al., 2021</xref>). Most BSIs with gram-positive bacteria may be caused by long-term or repeated placement of PICC and CVC (<xref rid="B47" ref-type="bibr">van den Bosch et&#160;al., 2021</xref>). Candida was the primary pathogen of fungal BSIs, but the positive rate of fungal blood culture was low. This may be related to the difficulty of fungal culture and the lack of specific detection methods (<xref rid="B33" ref-type="bibr">Pappas et&#160;al., 2018</xref>). Therefore, blood cultures should be drawn actively and repeated for patients with fever if necessary. Moreover, new detection methods, such as second-generation sequencing, help detect the fungus (<xref rid="B34" ref-type="bibr">Peri et&#160;al., 2022</xref>). When patients have a poor response to antibiotics, they should be alert to fungal infections and be treated with antifungal agents as soon as necessary (<xref rid="B14" ref-type="bibr">Freifeld et&#160;al., 2011</xref>). The distribution of pathogens in our study was distinct from a study from Spain (<xref rid="B15" ref-type="bibr">Garcia-Vidal et&#160;al., 2018</xref>). This may be due to differences in region and habits of medication.</p><p>With the extensive use of antibiotics, bacterial drug resistance is becoming more serious. The mechanisms of bacterial resistance include the production of inactive enzymes and modifying enzymes, the change of target sites, the expression of efflux pumps, and the reduced permeability of the bacterial outer membrane (<xref rid="B7" ref-type="bibr">Blair et&#160;al., 2015</xref>). Identifying patterns of local bacterial resistance is a prerequisite for selecting appropriate antibiotics. Our study found that <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic> were sensitive to carbapenem antibiotics and amikacin, and <italic toggle="yes">Pseudomonas aeruginosa</italic> was sensitive to amikacin. This result was consistent with other studies (<xref rid="B44" ref-type="bibr">Trecarichi et&#160;al., 2015</xref>; <xref rid="B52" ref-type="bibr">Zhao et&#160;al., 2020</xref>; <xref rid="B38" ref-type="bibr">Shi et&#160;al., 2022</xref>). The antibiotics above may be appropriate for the common BSIs with gram-negative bacteria in clinical practice. Compared to our study showing a low resistance rate of <italic toggle="yes">Pseudomonas aeruginosa</italic> to ciprofloxacin (2.5%), other studies have shown various resistance in <italic toggle="yes">Pseudomonas aeruginosa</italic> to ciprofloxacin (2.4%-80.3%) (<xref rid="B40" ref-type="bibr">Sligl et&#160;al., 2015</xref>; <xref rid="B44" ref-type="bibr">Trecarichi et&#160;al., 2015</xref>; <xref rid="B10" ref-type="bibr">Chen et&#160;al., 2017</xref>; <xref rid="B52" ref-type="bibr">Zhao et&#160;al., 2020</xref>). The inconsistent results among the studies may be due to regional differences and sample sizes. Common gram-positive bacteria were susceptible to tigecycline, linezolid, and vancomycin. In the present study, MRSA, MRCNS, and vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic> were also detected (<xref rid="B17" ref-type="bibr">Haddad et&#160;al., 2021</xref>). With the application of antibiotics, the emergence of extended-spectrum &#946;-lactamase-producing bacteria and MDR bacteria has become one of the thorniest problems. Therefore, it is necessary to have clear indications for the use of antibiotics. At the same time, the use of antibiotics must be cautious, and the distribution of local pathogens and drug-resistance results should be considered. Fungal infections were not uncommon in patients with HMs. In our hospital, <italic toggle="yes">Candida tropicalis</italic> was the most common. Amphotericin B, caspofungin, and micafungin were effective for patients with fungal BSIs in HMs. Xiao et&#160;al. found that the mortality of patients with fungal BSIs in HMs was 40.5%, much higher than that of patients with common fungal infections in HMs (<xref rid="B50" ref-type="bibr">Xiao et&#160;al., 2020</xref>). Therefore, it is vital to understand fungi&#8217;s distribution and drug resistance of fungi for treating fungal BSIs.</p><p>BSI was a common complication associated with high mortality in a patient with HM. The 30-day mortality was 29% in our study population, and other studies reported mortality ranging from 10% to 32% (<xref rid="B30" ref-type="bibr">N&#248;rgaard et&#160;al., 2006</xref>; <xref rid="B4" ref-type="bibr">&#197;ttman et&#160;al., 2015</xref>; <xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B9" ref-type="bibr">Chen et&#160;al., 2021</xref>). Some studies about the risk factors for the poor prognosis of patients with BSIs in HMs were published (<xref rid="B46" ref-type="bibr">Tumbarello et&#160;al., 2012</xref>; <xref rid="B45" ref-type="bibr">Trecarichi et&#160;al., 2016</xref>; <xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B38" ref-type="bibr">Shi et&#160;al., 2022</xref>). Nomograms are commonly used to evaluate the prognosis of tumor patients (<xref rid="B6" ref-type="bibr">Balachandran et&#160;al., 2015</xref>). We developed a nomogram for predicting the 30-day mortality of patients with BSIs in HMs. According to the evaluation with the c-indexes, calibration plots, and decision curves, the nomogram had satisfactory discrimination, consistency, and clinical benefit. The nomogram showed that septic shock, relapsed/refractory HM, albumin &lt;30g/l, platelets &lt;30&#215;10<sup>9</sup>/l before BSI, and inappropriate empiric antibiotic treatment were independent risk factors for 30-day mortality after BSI in patients with HMs.</p><p>A notable finding in our study was the identification of a previously unnoted risk factor for 30-day mortality, namely platelets &lt;30&#215;10<sup>9</sup>/l before BSI. Patients with HMs developed thrombocytopenia due to myelosuppression. After BSI, especially progression to sepsis, platelet levels in patients with HMs may decrease further (<xref rid="B16" ref-type="bibr">Ghimire et&#160;al., 2021</xref>). Platelets are essential in primary hemostasis and are also involved in angiogenesis, tissue repair, and inflammation (<xref rid="B48" ref-type="bibr">Vinholt, 2019</xref>). Menard et&#160;al. found that thrombocytopenia was associated with major bleeding events and increased mortality in patients with septic shock (<xref rid="B28" ref-type="bibr">Menard et&#160;al., 2019</xref>). Thus, patients with BSIs in HMs with platelets less than 30&#215;10<sup>9</sup>/l had a higher risk of death at 30 days, possibly because they were more prone to major bleeding. Therefore, attention should be paid to the patients with BSIs in HMs who had low platelet levels, and appropriate platelet transfusion should be given to improve the prognosis of patients.</p><p>Septic shock is characterized by systemic hypoperfusion, often leading to organ failure and high mortality (<xref rid="B8" ref-type="bibr">Cecconi et&#160;al., 2018</xref>). Our study and others confirmed that septic shock was an independent risk factor for death in patients with HMs after BSI (<xref rid="B13" ref-type="bibr">Criscuolo et&#160;al., 2019</xref>; <xref rid="B11" ref-type="bibr">Chen et&#160;al., 2020</xref>; <xref rid="B35" ref-type="bibr">Royo-Cebrecos et&#160;al., 2022</xref>). Patients with low oxygen saturation, hypotension, or disturbance of consciousness need to be identified early and intervened as soon as possible, including fluid resuscitation and vasopressors. The association between the state of HM and mortality had been previously determined (<xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B9" ref-type="bibr">Chen et&#160;al., 2021</xref>). We also found that relapsed/refractory HM was an independent risk factor for 30-day mortality after BSI in patients with HMs. Albumin is synthesized by the liver and reflects liver function and nutritional status. The study by Tang et&#160;al. suggested that albumin &lt;30g/l was closely related to 30-day mortality in patients with HMs and BSIs (<xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>). The same finding was confirmed in our study. Monitoring the albumin level and, if necessary, infusion of albumin is of great significance for the prognosis of patients with BSIs in HMs.</p><p>Empiric antibiotic therapy is one of the primary measures of anti-infection treatment. For patients with BSIs in HMs, the use of antibiotics is best based on the drug sensitivity, but it takes a while to wait for the blood culture results. The infection may further aggravate or even become life-threatening if antibiotics are not given in time. Previous studies have shown that inappropriate empiric antibiotic therapy was a risk factor for mortality in patients with BSIs among HMs (<xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B42" ref-type="bibr">Tang et&#160;al., 2020</xref>; <xref rid="B53" ref-type="bibr">Zhao et&#160;al., 2022</xref>). This was also confirmed in the present study. Empiric antibiotic therapy for patients with BSIs in HMs should be individualized, considering previous antibiotic use, current epidemiology, and appropriate guidelines (<xref rid="B14" ref-type="bibr">Freifeld et&#160;al., 2011</xref>; <xref rid="B12" ref-type="bibr">Chinese Society of Hematology et al., 2020</xref>). Other factors such as neutropenia, age, placement of the urinary catheter, and nosocomial infection were not ultimately included in the nomogram in our study, possibly because of differences in the population and region and the retrospective nature of the study (<xref rid="B46" ref-type="bibr">Tumbarello et&#160;al., 2012</xref>; <xref rid="B41" ref-type="bibr">Tang et&#160;al., 2018</xref>; <xref rid="B38" ref-type="bibr">Shi et&#160;al., 2022</xref>).</p><p>Our study has some limitations. First, our study is retrospective, with limited samples and biases, and we only conducted internal validation. External validation and prospective studies are needed to optimize our model. Second, our study was based on diagnostic, laboratory testing, and therapeutic regimens at a single center, and there may be regional differences in findings.</p><p>In conclusion, our study suggested that gram-negative bacterial BSIs were predominant in patients with HMs. Meanwhile, we found that septic shock, relapsed/refractory HM, albumin &lt;30g/l, platelets &lt;30&#215;10<sup>9</sup>/l before BSI, and inappropriate empiric antibiotic treatment were independent risk factors for 30-day mortality after BSI in patients with HMs. Based on these factors, the nomogram was developed and validated to have good predictive ability. It can be used to evaluate the prognosis of patients promptly for clinicians.</p></sec><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>West China Hospital of Sichuan University Ethics Committee approved this study (2022-1930).</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>JW collected clinical data, interpreted the results, wrote, and revised the manuscript. MW and AZ participated in collecting data, data statistics. HZ and MM revised the manuscript. XL checked statistical methods. TN participated in the study design and revised the manuscript. All authors contributed to the article and approved the submitted version.</p></sec></body><back><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albasanz-Puig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gudiol</surname><given-names>C.</given-names></name><name name-style="western"><surname>Puerta-Alcalde</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ayaz</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Impact of the inclusion of an aminoglycoside to the initial empirical antibiotic therapy for gram-negative bloodstream infections in hematological neutropenic patients: a propensity-matched cohort study (AMINOLACTAM study)</article-title>. <source>Antimicrob. Agents Chemother.</source><volume>65</volume> (<issue>8</issue>), <fpage>e0004521</fpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00045-21</pub-id><pub-id pub-id-type="pmid">33972253</pub-id><pub-id pub-id-type="pmcid">PMC8284470</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amanati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sajedianfard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khajeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghasempour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehrangiz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nematolahi</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance</article-title>. <source>BMC Infect. Dis.</source><volume>21</volume> (<issue>1</issue>), <fpage>636</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12879-021-06243-z</pub-id><pub-id pub-id-type="pmid">34215207</pub-id><pub-id pub-id-type="pmcid">PMC8254331</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hiranuma</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takayanagi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>M. K.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Predictive model for the preoperative assessment and prognostic modeling of lymph node metastasis in endometrial cancer</article-title>. <source>Sci. Rep.</source><volume>12</volume> (<issue>1</issue>), <fpage>19004</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/41598-022-23252-3</pub-id><pub-id pub-id-type="pmid">36347927</pub-id><pub-id pub-id-type="pmcid">PMC9643353</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#197;ttman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aittoniemi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sinisalo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vuento</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lyytik&#228;inen</surname><given-names>O.</given-names></name><name name-style="western"><surname>K&#228;rki</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Etiology, clinical course and outcome of healthcare-associated bloodstream infections in patients with hematological malignancies: a retrospective study of 350 patients in a Finnish tertiary care hospital</article-title>. <source>Leuk. Lymphoma</source><volume>56</volume> (<issue>12</issue>), <fpage>3370</fpage>&#8211;<lpage>3377</lpage>. doi: <pub-id pub-id-type="doi">10.3109/10428194.2015.1032967</pub-id><pub-id pub-id-type="pmid">25813080</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auberger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tamburini-Bonnefoy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Puissant</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Drug resistance in hematological malignancies</article-title>. <source>Int. J. Mol. Sci.</source><volume>21</volume> (<issue>17</issue>), <fpage>6091</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21176091</pub-id><pub-id pub-id-type="pmid">32847013</pub-id><pub-id pub-id-type="pmcid">PMC7503602</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balachandran</surname><given-names>V. P.</given-names></name><name name-style="western"><surname>Gonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>DeMatteo</surname><given-names>R. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Nomograms in oncology: more than meets the eye</article-title>. <source>Lancet Oncol.</source><volume>16</volume> (<issue>4</issue>), <fpage>e173</fpage>&#8211;<lpage>e180</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(14)71116-7</pub-id><pub-id pub-id-type="pmid">25846097</pub-id><pub-id pub-id-type="pmcid">PMC4465353</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blair</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Webber</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Baylay</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Ogbolu</surname><given-names>D. O.</given-names></name><name name-style="western"><surname>Piddock</surname><given-names>L. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Molecular mechanisms of antibiotic resistance</article-title>. <source>Nat. Rev. Microbiol.</source><volume>13</volume> (<issue>1</issue>), <fpage>42</fpage>&#8211;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrmicro3380</pub-id><pub-id pub-id-type="pmid">25435309</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cecconi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>L.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Sepsis and septic shock</article-title>. <source>Lancet (London England)</source><volume>392</volume> (<issue>10141</issue>), <fpage>75</fpage>&#8211;<lpage>87</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)30696-2</pub-id><pub-id pub-id-type="pmid">29937192</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy</article-title>. <source>J. Cancer</source><volume>12</volume> (<issue>18</issue>), <fpage>5494</fpage>&#8211;<lpage>5505</lpage>. doi: <pub-id pub-id-type="doi">10.7150/jca.50802</pub-id><pub-id pub-id-type="pmid">34405012</pub-id><pub-id pub-id-type="pmcid">PMC8364636</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Tien</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J. L.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008-2013</article-title>. <source>Int. J. Antimicrob. Agents</source><volume>49</volume> (<issue>3</issue>), <fpage>272</fpage>&#8211;<lpage>281</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.11.009</pub-id><pub-id pub-id-type="pmid">28109554</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X. C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D. P.</given-names></name></person-group> (<year>2020</year>). <article-title>Clinical characteristics and outcomes of breakthrough candidemia in 71 hematologic malignancy patients and/or allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study from China, 2011-2018</article-title>. <source>Clin. Infect. Dis.</source><volume>71</volume> (<issue>Suppl 4</issue>), <fpage>S394</fpage>&#8211;<lpage>S3s9</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciaa1523</pub-id><pub-id pub-id-type="pmid">33367573</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Chinese Society of Hematology, Chinese Medical Association, Chinese Medical Doctor Association, Hematology Branch</collab></person-group>. (<year>2020</year>). <article-title>[Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020)]</article-title>. <source>Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi</source><volume>41</volume> (<issue>12</issue>), <fpage>969</fpage>&#8211;<lpage>978</lpage>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.issn.0253-2727.2020.12.001</pub-id><pub-id pub-id-type="pmid">33445842</pub-id><pub-id pub-id-type="pmcid">PMC7840550</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Criscuolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marchesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Candoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nosari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Veggia</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Fungaemia in haematological malignancies: SEIFEM-2015 survey</article-title>. <source>Eur. J. Clin. Invest.</source><volume>49</volume> (<issue>5</issue>), <fpage>e13083</fpage>. doi: <pub-id pub-id-type="doi">10.1111/eci.13083</pub-id><pub-id pub-id-type="pmid">30735240</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freifeld</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Bow</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Sepkowitz</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Boeckh</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Mullen</surname><given-names>C. A.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america</article-title>. <source>Clin. Infect. Dis.</source><volume>52</volume> (<issue>4</issue>), <fpage>e56</fpage>&#8211;<lpage>e93</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/cir073</pub-id><pub-id pub-id-type="pmid">21258094</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Vidal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cardozo-Espinola</surname><given-names>C.</given-names></name><name name-style="western"><surname>Puerta-Alcalde</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tellez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ag&#252;ero</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance</article-title>. <source>PloS One</source><volume>13</volume> (<issue>6</issue>), <fpage>e0199531</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0199531</pub-id><pub-id pub-id-type="pmid">29953464</pub-id><pub-id pub-id-type="pmcid">PMC6023133</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghimire</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Budhathoki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arjyal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hamal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bista</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Current understanding and future implications of sepsis-induced thrombocytopenia</article-title>. <source>Eur. J. Haematol.</source><volume>106</volume> (<issue>3</issue>), <fpage>301</fpage>&#8211;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ejh.13549</pub-id><pub-id pub-id-type="pmid">33191517</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jabbour</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Hindy</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Makki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nayfeh</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Bacterial bloodstream infections and patterns of resistance in patients with haematological malignancies at a tertiary centre in Lebanon over 10 years</article-title>. <source>J. Global Antimicrob. Resist.</source><volume>27</volume>, <fpage>228</fpage>&#8211;<lpage>235</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgar.2021.09.008</pub-id><pub-id pub-id-type="pmid">34607062</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huttunen</surname><given-names>R.</given-names></name><name name-style="western"><surname>&#197;ttman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aittoniemi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Outinen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Syrj&#228;nen</surname><given-names>J.</given-names></name><name name-style="western"><surname>K&#228;rki</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Nosocomial bloodstream infections in a Finnish tertiary care hospital: a retrospective cohort study of 2175 episodes during the years 1999-2001 and 2005-2010</article-title>. <source>Infect. Dis. (London England)</source><volume>47</volume> (<issue>1</issue>), <fpage>20</fpage>&#8211;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.3109/00365548.2014.956791</pub-id><pub-id pub-id-type="pmid">25351869</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kadri</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Strich</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Babiker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ricotta</surname><given-names>E. E.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume> (<issue>2</issue>), <fpage>241</fpage>&#8211;<lpage>251</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30477-1</pub-id><pub-id pub-id-type="pmid">32916100</pub-id><pub-id pub-id-type="pmcid">PMC7855478</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Hiramoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hosono</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan adult leukemia study group AML201 protocols</article-title>. <source>Support. Care Cancer</source><volume>26</volume> (<issue>12</issue>), <fpage>4187</fpage>&#8211;<lpage>4198</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00520-018-4292-0</pub-id><pub-id pub-id-type="pmid">29860713</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kern</surname><given-names>W. V.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dettenkofer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaier</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bertz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Behnke</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014</article-title>. <source>J. Infect.</source><volume>77</volume> (<issue>1</issue>), <fpage>68</fpage>&#8211;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jinf.2018.05.004</pub-id><pub-id pub-id-type="pmid">29883599</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kochanek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schalk</surname><given-names>E.</given-names></name><name name-style="western"><surname>von Bergwelt-Baildon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beutel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Buchheidt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hentrich</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Management of sepsis in neutropenic cancer patients: 2018 guidelines from the infectious diseases working party (AGIHO) and intensive care working party (iCHOP) of the German society of hematology and medical oncology (DGHO)</article-title>. <source>Ann. Hematol.</source><volume>98</volume> (<issue>5</issue>), <fpage>1051</fpage>&#8211;<lpage>1069</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00277-019-03622-0</pub-id><pub-id pub-id-type="pmid">30796468</pub-id><pub-id pub-id-type="pmcid">PMC6469653</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J. S.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Bloodstream infections in pediatric patients with acute leukemia: emphasis on gram-negative bacteria infections</article-title>. <source>J. Microbiol. Immunol. Infect. = Wei mian yu gan ran za zhi</source><volume>50</volume> (<issue>4</issue>), <fpage>507</fpage>&#8211;<lpage>513</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jmii.2015.08.013</pub-id><pub-id pub-id-type="pmid">26442676</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>W. C.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C. Y.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Changing epidemiology and prognosis of nosocomial bloodstream infection: a single-center retrospective study in Taiwan</article-title>. <source>J. Microbiol. Immunol. Infect</source>. <volume>55</volume> (<issue>6 Pt 2</issue>), <page-range>1293&#8211;1300</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jmii.2021.09.015</pub-id><pub-id pub-id-type="pmid">34674959</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Q.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>A multicenter, prospective evaluation of the Chinese society of thrombosis and hemostasis scoring system for disseminated intravascular coagulation</article-title>. <source>Thromb. Res.</source><volume>173</volume>, <fpage>131</fpage>&#8211;<lpage>140</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.thromres.2018.11.022</pub-id><pub-id pub-id-type="pmid">30529391</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magiorakos</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Carmeli</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Falagas</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Giske</surname><given-names>C. G.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</article-title>. <source>Clin. Microbiol. Infect.</source><volume>18</volume> (<issue>3</issue>), <fpage>268</fpage>&#8211;<lpage>281</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id><pub-id pub-id-type="pmid">21793988</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gudiol</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ardanuy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garcia-Vidal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arnan</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours</article-title>. <source>J. Infect.</source><volume>69</volume> (<issue>5</issue>), <fpage>417</fpage>&#8211;<lpage>423</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jinf.2014.05.018</pub-id><pub-id pub-id-type="pmid">24960295</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menard</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Houston</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Turgeon</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Rimmer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Houston</surname><given-names>B. L.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Evolution and impact of thrombocytopenia in septic shock: a retrospective cohort study</article-title>. <source>Crit. Care Med.</source><volume>47</volume> (<issue>4</issue>), <fpage>558</fpage>&#8211;<lpage>565</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CCM.0000000000003644</pub-id><pub-id pub-id-type="pmid">30855327</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mimura</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akazawa</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study</article-title>. <source>Ann. Clin. Microbiol. Antimicrob.</source><volume>19</volume> (<issue>1</issue>), <fpage>7</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12941-020-00348-0</pub-id><pub-id pub-id-type="pmid">32066448</pub-id><pub-id pub-id-type="pmcid">PMC7027235</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#248;rgaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sch&#248;nheyder</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>H. T.</given-names></name></person-group> (<year>2006</year>). <article-title>Risk of bacteraemia and mortality in patients with haematological malignancies</article-title>. <source>Clin. Microbiol. Infect.</source><volume>12</volume> (<issue>3</issue>), <fpage>217</fpage>&#8211;<lpage>223</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1469-0691.2005.01298.x</pub-id><pub-id pub-id-type="pmid">16451407</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamoto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kanda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Oyake</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study</article-title>. <source>Int. J. Hematol.</source><volume>114</volume> (<issue>4</issue>), <fpage>472</fpage>&#8211;<lpage>482</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12185-021-03183-x</pub-id><pub-id pub-id-type="pmid">34170481</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortega</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rovira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almela</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marco</surname><given-names>F.</given-names></name><name name-style="western"><surname>de la Bellacasa</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J. A.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000</article-title>. <source>Ann. Hematol.</source><volume>84</volume> (<issue>1</issue>), <fpage>40</fpage>&#8211;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00277-004-0909-0</pub-id><pub-id pub-id-type="pmid">15480665</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Lionakis</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Arendrup</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Ostrosky-Zeichner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kullberg</surname><given-names>B. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Invasive candidiasis</article-title>. <source>Nat. Rev. Dis. Primers</source><volume>4</volume>, <fpage>18026</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrdp.2018.26</pub-id><pub-id pub-id-type="pmid">29749387</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peri</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>P. N. A.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>D. L.</given-names></name></person-group> (<year>2022</year>). <article-title>Culture-independent detection systems for bloodstream infection</article-title>. <source>Clin. Microbiol. Infect.</source><volume>28</volume> (<issue>2</issue>), <fpage>195</fpage>&#8211;<lpage>201</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmi.2021.09.039</pub-id><pub-id pub-id-type="pmid">34687856</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Royo-Cebrecos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Laporte-Amarg&#243;s</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruiz-Camps</surname><given-names>I.</given-names></name><name name-style="western"><surname>Puerta-Alcalde</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abdala</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Pseudomonas aeruginosa bloodstream infections in patients with cancer: differences between patients with hematological malignancies and solid tumors</article-title>. <source>Pathog. (Basel Switzerland)</source><volume>11</volume> (<issue>10</issue>), <fpage>1132</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens11101132</pub-id><pub-id pub-id-type="pmcid">PMC9610728</pub-id><pub-id pub-id-type="pmid">36297188</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safdar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>Balakrishnan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tarrand</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Rolston</surname><given-names>K. V.</given-names></name></person-group> (<year>2006</year>). <article-title>Changing trends in etiology of bacteremia in patients with cancer</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source><volume>25</volume> (<issue>8</issue>), <fpage>522</fpage>&#8211;<lpage>526</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10096-006-0173-4</pub-id><pub-id pub-id-type="pmid">16896827</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schelenz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nwaka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>P. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance</article-title>. <source>J. Antimicrob. Chemother.</source><volume>68</volume> (<issue>6</issue>), <fpage>1431</fpage>&#8211;<lpage>1438</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkt002</pub-id><pub-id pub-id-type="pmid">23396855</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Bacteriological profile and antimicrobial susceptibility patterns of gram-negative bloodstream infection and risk factors associated with mortality and drug resistance: a retrospective study from shanxi, China</article-title>. <source>Infect. Drug Resist.</source><volume>15</volume>, <fpage>3561</fpage>&#8211;<lpage>3578</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S370326</pub-id><pub-id pub-id-type="pmid">35833010</pub-id><pub-id pub-id-type="pmcid">PMC9271686</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deutschman</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Shankar-Hari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Annane</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title>. <source>Jama</source><volume>315</volume> (<issue>8</issue>), <fpage>801</fpage>&#8211;<lpage>810</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmid">26903338</pub-id><pub-id pub-id-type="pmcid">PMC4968574</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sligl</surname><given-names>W. I.</given-names></name><name name-style="western"><surname>Dragan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S. W.</given-names></name></person-group> (<year>2015</year>). <article-title>Nosocomial gram-negative bacteremia in intensive care: epidemiology, antimicrobial susceptibilities, and outcomes</article-title>. <source>Int. J. Infect. Dis.: IJID</source><volume>37</volume>, <fpage>129</fpage>&#8211;<lpage>134</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2015.06.024</pub-id><pub-id pub-id-type="pmid">26159847</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections</article-title>. <source>Infection</source><volume>46</volume> (<issue>4</issue>), <fpage>513</fpage>&#8211;<lpage>521</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s15010-018-1151-3</pub-id><pub-id pub-id-type="pmid">29767394</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Inappropriate initial antimicrobial therapy for hematological malignancies patients with gram-negative bloodstream infections</article-title>. <source>Infection</source><volume>48</volume> (<issue>1</issue>), <fpage>109</fpage>&#8211;<lpage>116</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s15010-019-01370-x</pub-id><pub-id pub-id-type="pmid">31677085</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timsit</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Rupp&#233;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barbier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tabah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Bloodstream infections in critically ill patients: an expert statement</article-title>. <source>Intensive Care Med.</source><volume>46</volume> (<issue>2</issue>), <fpage>266</fpage>&#8211;<lpage>284</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00134-020-05950-6</pub-id><pub-id pub-id-type="pmid">32047941</pub-id><pub-id pub-id-type="pmcid">PMC7223992</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trecarichi</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Candoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pastore</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fanci</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey</article-title>. <source>Clin. Microbiol. Infect.</source><volume>21</volume> (<issue>4</issue>), <fpage>337</fpage>&#8211;<lpage>343</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmi.2014.11.022</pub-id><pub-id pub-id-type="pmid">25595706</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trecarichi</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martino</surname><given-names>B.</given-names></name><name name-style="western"><surname>Candoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Blasi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nadali</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Bloodstream infections caused by klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey</article-title>. <source>Am. J. Hematol.</source><volume>91</volume> (<issue>11</issue>), <fpage>1076</fpage>&#8211;<lpage>1081</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ajh.24489</pub-id><pub-id pub-id-type="pmid">27428072</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tumbarello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trecarichi</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Caira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Candoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pastore</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cattaneo</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality</article-title>. <source>PloS One</source><volume>7</volume> (<issue>12</issue>), <fpage>e51612</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0051612</pub-id><pub-id pub-id-type="pmid">23272123</pub-id><pub-id pub-id-type="pmcid">PMC3522733</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Bosch</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>van Woensel</surname><given-names>J.</given-names></name><name name-style="western"><surname>van de Wetering</surname><given-names>M. D.</given-names></name></person-group> (<year>2021</year>). <article-title>Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancer</article-title>. <source>Cochrane Database System. Rev.</source><volume>10</volume> (<issue>10</issue>), <fpage>Cd003295</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1002/14651858.CD003295.pub4</pub-id><pub-id pub-id-type="pmid">34617602</pub-id><pub-id pub-id-type="pmcid">PMC8495768</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinholt</surname><given-names>P. J.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of platelets in bleeding in patients with thrombocytopenia and hematological disease</article-title>. <source>Clin. Chem. Lab. Med.</source><volume>57</volume> (<issue>12</issue>), <fpage>1808</fpage>&#8211;<lpage>1817</lpage>. doi: <pub-id pub-id-type="doi">10.1515/cclm-2019-0380</pub-id><pub-id pub-id-type="pmid">31465290</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Son</surname><given-names>T.</given-names></name><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okumura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>G. S.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>A novel prediction model of prognosis after gastrectomy for gastric carcinoma: development and validation using Asian databases</article-title>. <source>Ann. Surg.</source><volume>264</volume> (<issue>1</issue>), <fpage>114</fpage>&#8211;<lpage>120</lpage>. doi: <pub-id pub-id-type="doi">10.1097/SLA.0000000000001523</pub-id><pub-id pub-id-type="pmid">26945155</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Risk prediction and prognosis of invasive fungal disease in hematological malignancies patients complicated with bloodstream infections</article-title>. <source>Cancer Manage. Res.</source><volume>12</volume>, <fpage>2167</fpage>&#8211;<lpage>2175</lpage>. doi: <pub-id pub-id-type="doi">10.2147/CMAR.S238166</pub-id><pub-id pub-id-type="pmcid">PMC7102877</pub-id><pub-id pub-id-type="pmid">32273756</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>Dynamic prediction and prognostic analysis of patients with cervical cancer: a landmarking analysis approach</article-title>. <source>Ann. Epidemiol.</source><volume>44</volume>, <fpage>45</fpage>&#8211;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annepidem.2020.01.009</pub-id><pub-id pub-id-type="pmid">32220511</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Risk factors and outcomes of antibiotic-resistant pseudomonas aeruginosa bloodstream infection in adult patients with acute leukemia</article-title>. <source>Clin. Infect. Dis.</source><volume>71</volume> (<issue>Suppl 4</issue>), <fpage>S386</fpage>&#8211;<lpage>Ss93</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciaa1522</pub-id><pub-id pub-id-type="pmid">33367574</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Pseudomonas aeruginosa bloodstream infection in patients with hematological diseases: clinical outcomes and prediction model of multidrug-resistant infections</article-title>. <source>J. Infect.</source><volume>86</volume> (<issue>1</issue>), <page-range>66&#8211;117</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jinf.2022.08.037</pub-id><pub-id pub-id-type="pmid">36064048</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Development and validation of a novel survival prediction model for newly diagnosed lower-grade gliomas</article-title>. <source>Neurosurg. Focus</source><volume>52</volume> (<issue>4</issue>), <fpage>E13</fpage>. doi: <pub-id pub-id-type="doi">10.3171/2022.1.FOCUS21596</pub-id><pub-id pub-id-type="pmid">35364578</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>